Two Blades Foundation Licenses TAL Code Technology to Monsanto
News Apr 18, 2012
The Two Blades Foundation (2Blades) has completed a non-exclusive license agreement with the Monsanto Company for access to the TAL Code technology for genome engineering in plants.
The Transcription Activator Like (TAL) effector Code technology, discovered by Ulla Bonas, Jens Boch, Thomas Lahaye, and Sebastian Schornack at Martin-Luther University in Halle, Germany, is based on novel sequence-specific DNA-binding proteins that can be designed quickly and easily to recognize virtually any sequence of interest.
Named Method of the Year in 2011 by the journal Nature Methods (9:1 doi:10.1038/nmeth.1852), the technology enables a number of highly useful tools to target specific loci in a genome and modulate the expression of genes.
The application of these tools in plants will accelerate improvements in crop growth and development.
The Two Blades Foundation holds exclusive rights for commercial uses of the technology in plants.
“Having Monsanto, the world’s largest seed company, put the TAL Code technology to use in their programs will further ensure its wide use and development,” said 2Blades Chief Operating Officer Diana Horvath.
2Blades will gain access to Monsanto’s improvements to the technology for use in 2Blades’ humanitarian efforts in support of subsistence farming.
The license agreement will aid Monsanto’s mission to develop high quality products for sustainable agriculture through science-based solutions. Financial terms of the agreement were not disclosed.
New Approach Identifies Important Undiscovered Functions of ProteinsNews
Scientists have developed a new method to discover which surface contacts on proteins are critical for these cellular interactions. The novel approach shows that essential new functions can be uncovered even for well-studied proteins, and has significant implications for therapeutic drug development, which depends heavily on how drugs physically interact with their cellular targets.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE